What is the clinically effective dose of CBD for epilepsy?

In FDA-approved trials for Dravet syndrome and Lennox-Gastaut syndrome, pharmaceutical CBD (Epidiolex) was initiated at 5 mg/kg/day and titrated to 20 mg/kg/day, producing median seizure reductions of approximately 38–39% versus 13–14% for placebo. Consumer supplement doses averaging 25 mg/day are far below clinically validated therapeutic levels and should not be used as a substitute for prescribed antiepileptic therapy.

Does CBD get you high?

CBD does not produce psychoactive effects because its binding affinity for CB1 receptors (Ki approximately 4,350 nM) is approximately 100-fold lower than that of THC (Ki approximately 40.7 nM), meaning it does not meaningfully activate the receptor responsible for THC's intoxicating effects. Additionally, CBD is approximately 90% plasma protein bound, further reducing the free pharmacologically active fraction available to interact with central nervous system receptors. At any clinically or commercially relevant dose, CBD does not cause euphoria, impaired cognition, or the characteristic high associated with THC.

What are the main drug interactions of CBD?

CBD inhibits cytochrome P450 enzymes CYP3A4 and CYP2C19, raising plasma levels of co-administered drugs including clobazam, warfarin, certain antiepileptics, and CYP3A4 substrates, with potential for serious toxicity. Concomitant use with valproate additionally increases the risk of liver enzyme elevation. Patients on any medications should seek medical guidance before initiating CBD supplementation.

How bioavailable is oral CBD and how can I improve absorption?

Oral CBD bioavailability is approximately 6% under fasted conditions but increases substantially when taken with a high-fat meal due to enhanced lymphatic absorption of this lipophilic compound. Peak oral plasma concentrations are reached around 120 minutes post-dose. Inhalation achieves approximately 31% bioavailability with onset in 3–10 minutes, though this route is not advisable for general wellness use due to respiratory concerns.

Is CBD safe during pregnancy or breastfeeding?

Safety data for CBD in pregnancy and lactation are insufficient to establish human risk profiles; cannabinoids cross the placental barrier and are detectable in breast milk. The FDA explicitly advises against nonprescription CBD use during pregnancy and breastfeeding due to potential developmental risks. Use during these periods should only occur under direct medical supervision with a clear therapeutic indication outweighing potential risks.

What does clinical research show about CBD's effectiveness for anxiety?

Preliminary human studies and extensive preclinical research suggest CBD has anxiolytic properties, though most evidence remains limited compared to its epilepsy applications. A 2019 observational study found CBD reduced anxiety in 79.2% of patients within the first month, but larger randomized controlled trials are needed to establish optimal dosing and efficacy compared to standard anxiolytics. Current evidence supports CBD as a potential adjunct for anxiety, but it is not yet FDA-approved for this indication.

Who should avoid CBD supplementation or use it with caution?

Individuals taking medications metabolized by the CYP3A4 or CYP2C19 enzymes should use CBD cautiously due to potential drug interactions, as should those with liver impairment or severe hypotension. People scheduled for surgery should inform their healthcare provider about CBD use, as it may potentiate anesthetic effects. Those with a personal or family history of psychosis should consult a healthcare provider before use, as high-dose CBD may theoretically worsen psychotic symptoms in susceptible individuals.

How does CBD's mechanism of action differ between its antiepileptic and anxiolytic effects?

CBD's antiepileptic activity primarily involves modulation of voltage-gated sodium channels and antagonism of the GPR55 receptor, reducing abnormal neuronal firing in seizure disorders. Its anxiolytic effects appear to involve different pathways, including serotonin 5-HT1A receptor agonism and modulation of GABA signaling in brain regions associated with fear and stress responses. These distinct mechanisms explain why CBD may be effective for different neurological conditions through overlapping but separate neural targets.

Cannabidiol

Cannabidiol is a nonpsychoactive phytocannabinoid from Cannabis sativa that exerts its effects through weak modulation of CB1 and CB2 cannabinoid receptors, serotonin 5-HT1A receptors, and multiple ion channels rather than direct psychoactive receptor agonism. Its most clinically validated application is in drug-resistant epilepsy syndromes, where the FDA-approved formulation Epidiolex demonstrated statistically significant seizure frequency reductions in randomized controlled trials at doses up to 20 mg/kg/day.

Category: Compound Evidence: 1/10 Tier: Strong

Origin & History

Cannabidiol (CBD) is a naturally occurring phytocannabinoid derived primarily from Cannabis sativa, a plant with origins in Central Asia that has been cultivated globally for millennia. CBD concentrations vary markedly by plant tissue and cultivar, ranging from approximately 1,790 µg/g in leaves to 8,590 µg/g in flowers of wild hemp, with processed biomass reaching concentrations near 8.84% by weight. Modern industrial hemp cultivars are selectively bred to maximize CBD while minimizing delta-9-tetrahydrocannabinol (THC), and the plant thrives in temperate climates across North America, Europe, and parts of Asia.

Historical & Cultural Context

Cannabis sativa has been documented in human use for at least 5,000 years, with early records from ancient China describing its use in fiber, food (hemp seed), and medicine, including the treatment of pain and convulsions in texts such as the Shennong Bencao Jing. Traditional Ayurvedic and Middle Eastern medical systems employed cannabis preparations for analgesic, sedative, and anti-inflammatory purposes, though these preparations were not CBD-specific and likely contained variable THC concentrations. The isolation of CBD as a distinct chemical compound was first achieved by Roger Adams at the University of Illinois in 1940, though its complete stereochemical structure was not elucidated until Raphael Mechoulam and colleagues published their landmark work in 1963. The modern resurgence of scientific and commercial interest in CBD accelerated dramatically after publicized case reports of CBD-enriched cannabis reducing seizure frequency in children with Dravet syndrome around 2013, ultimately culminating in the first FDA approval of a plant-derived cannabinoid pharmaceutical in 2018.

Health Benefits

- **Antiepileptic Activity**: CBD demonstrated significant reductions in seizure frequency in Dravet syndrome and Lennox-Gastaut syndrome in randomized controlled trials, leading to FDA approval of Epidiolex; mechanisms likely involve modulation of voltage-gated sodium channels and GPR55 receptor antagonism.
- **Anxiolytic Effects**: Preclinical and preliminary human studies suggest CBD reduces anxiety-related behaviors through partial agonism at serotonin 5-HT1A receptors and modulation of limbic system activity, though large-scale RCTs in clinical anxiety disorders remain limited.
- **Anti-Inflammatory Properties**: CBD inhibits pro-inflammatory cytokine production and modulates the endocannabinoid system indirectly by inhibiting fatty acid amide hydrolase (FAAH), increasing endogenous anandamide levels, which may reduce neuroinflammation and peripheral inflammatory signaling.
- **Neuroprotective Potential**: In preclinical models, CBD reduces oxidative stress and excitotoxicity partly through its antioxidant properties and modulation of adenosine signaling, suggesting potential utility in neurodegenerative conditions, though human clinical evidence remains at an early stage.
- **Pancreatic and Metabolic Effects**: At concentrations of 0.1–100 µM in cell studies, CBD has been observed to increase insulin release and reduce oxidative stress in pancreatic tissue, indicating possible relevance to metabolic health, though this has not been confirmed in robust human trials.
- **Analgesic Adjunct**: CBD may reduce pain signaling through TRPV1 receptor desensitization and endocannabinoid potentiation, and it is investigated as an adjunct for neuropathic and inflammatory pain, with supportive preclinical evidence and mixed results in early human studies.
- **Sleep Quality**: Emerging evidence suggests CBD may improve sleep by reducing anxiety and modulating circadian adenosine pathways, though current clinical data are predominantly from open-label studies and anecdotal reports rather than double-blind RCTs.

How It Works

CBD exhibits weak direct binding to the two primary cannabinoid receptors, with Ki values of approximately 4,350 nM at CB1 and 2,860 nM at CB2—roughly 100-fold lower affinity than THC—which explains its absence of psychoactive effects even at high doses. Rather than direct receptor agonism, CBD's pharmacological activity is largely attributed to indirect mechanisms: it inhibits FAAH, the enzyme that degrades the endocannabinoid anandamide, thereby increasing endogenous cannabinoid tone; it acts as an antagonist at GPR55, a lysophosphatidylinositol receptor implicated in seizure activity; and it is a partial agonist at serotonin 5-HT1A receptors, contributing to anxiolytic and anticonvulsant effects. CBD also modulates voltage-gated sodium channels and transient receptor potential (TRP) channels including TRPV1 and TRPA1, which are relevant to its analgesic and anti-inflammatory properties. Approximately 90% of circulating CBD is plasma protein bound, meaning the pharmacologically active free-drug fraction is substantially reduced, and Ki values for nine additional receptor systems exceeded 1 µM, indicating minimal clinically significant direct off-target receptor interactions at physiological concentrations.

Scientific Research

The strongest clinical evidence for CBD exists in pediatric epilepsy: multiple Phase 3 randomized, double-blind, placebo-controlled trials of pharmaceutical-grade CBD (Epidiolex) in Dravet syndrome and Lennox-Gastaut syndrome demonstrated statistically significant reductions in convulsive seizure frequency compared to placebo, supporting FDA approval in 2018. Evidence for anxiety, pain, sleep, and other indications is substantially weaker, consisting primarily of small Phase 1/2 trials, open-label studies, and preclinical models rather than adequately powered RCTs. Clinical trial doses typically range from 150–1,500 mg/day, far exceeding the average 25 mg found in commercial supplement products, raising significant questions about whether consumer-grade CBD products deliver therapeutically relevant exposures. Overall, the evidence base is robust for epilepsy but preliminary-to-moderate for all other indications, and placebo-controlled research must account for the documented strong 'meaning effect' (expectation-driven placebo response) observed with CBD.

Clinical Summary

FDA-approved trials of pharmaceutical CBD (Epidiolex) at 10–20 mg/kg/day in children with Dravet syndrome and Lennox-Gastaut syndrome demonstrated median reductions in monthly convulsive seizure rates of approximately 38–39% compared to 13–14% for placebo, with statistical significance across multiple studies. Outside of epilepsy, a landmark crossover RCT in social anxiety disorder found that a single 600 mg oral dose of CBD significantly reduced anxiety during a simulated public speaking task versus placebo, but this single-dose model does not translate directly to chronic dosing regimens. Clinical trials for pain, PTSD, and psychosis have produced inconsistent results, often limited by small sample sizes, short durations, variable CBD formulations, and inadequate blinding. Confidence in CBD's clinical efficacy is high specifically for drug-resistant epilepsy syndromes and moderate-to-low for other therapeutic targets pending larger, well-controlled trials.

Nutritional Profile

CBD is a pure phytochemical compound (molecular formula C21H30O2, molecular weight 314.46 g/mol) rather than a nutritional macronutrient or micronutrient, and it does not contribute meaningful caloric, protein, carbohydrate, or fat content at supplemental doses. In its natural plant matrix, Cannabis sativa flowers and leaves also contain terpenes such as myrcene, limonene, and beta-caryophyllene, flavonoids including cannflavin A and B, and minor cannabinoids (CBG, CBN, cannabichromene) that may contribute to the 'entourage effect' in whole-plant extracts. CBD itself is highly lipophilic (log P approximately 6.3), is approximately 90% plasma protein bound upon absorption, and has an oral bioavailability of approximately 6% in standard formulations, increasing substantially when co-administered with lipid-rich food. The acidic biosynthetic precursor CBDA is present in raw plant material and converts to CBD through decarboxylation at temperatures above approximately 120°C.

Preparation & Dosage

- **FDA-Approved Oral Solution (Epidiolex)**: 2.5 mg/kg twice daily (5 mg/kg/day) as starting dose, titrated to a maximum of 10–20 mg/kg/day for Dravet and Lennox-Gastaut syndromes; administered with food to improve absorption.
- **Oral CBD Oil/Tincture (Supplement Grade)**: Typical commercial doses range from 15–50 mg per serving; sublingually held for 60–90 seconds before swallowing may modestly improve absorption over direct ingestion.
- **Oral Capsules/Softgels**: Doses of 25–75 mg/day commonly used in consumer products; oral bioavailability is approximately 6%, strongly enhanced when taken with a high-fat meal due to CBD's lipophilic nature.
- **Inhaled CBD (Vaporized)**: Bioavailability approximately 31% with peak plasma concentrations in 3–10 minutes; doses vary widely and are difficult to standardize; not recommended for medical use due to respiratory risks.
- **Rectal Suppositories**: Bioavailability approximately two-fold higher than oral due to bypass of first-pass hepatic metabolism; used in some clinical contexts but not widely available commercially.
- **Standardization**: Pharmaceutical-grade CBD products are standardized to >98% pure cannabidiol; consumer products vary enormously and third-party certificate of analysis verification is essential.
- **Timing Note**: Oral CBD should be taken with fatty foods to maximize bioavailability; half-life after prolonged administration extends to 2–5 days, suggesting steady-state is reached after approximately 10–25 days of daily dosing.

Synergy & Pairings

CBD combined with THC in a roughly 1:1 ratio, as found in the pharmaceutical formulation nabiximols (Sativex), demonstrates synergistic pain-modulating and spasticity-reducing effects compared to either cannabinoid alone, attributed to complementary CB1/CB2 receptor engagement and reduced psychoactivity from CBD's partial CB1 antagonism moderating THC's psychoactive binding. The terpene beta-caryophyllene, a selective CB2 agonist present in full-spectrum hemp extracts, may augment CBD's anti-inflammatory and analgesic activity through parallel endocannabinoid pathway engagement, supporting the concept of the 'entourage effect' in whole-plant versus isolate formulations. Coadministration of CBD with piperine (from black pepper) has been theorized to enhance bioavailability through CYP3A4 inhibition, though this interaction also carries the risk of unintended drug-drug interaction amplification and should be approached cautiously in clinical contexts.

Safety & Interactions

At doses used in FDA-approved pharmaceutical trials (10–20 mg/kg/day), the most commonly reported adverse effects of CBD include somnolence, decreased appetite, diarrhea, elevated liver transaminases (particularly at doses above 20 mg/kg/day or when co-administered with valproate), and fatigue; at typical consumer supplement doses of 25–75 mg/day, the adverse effect profile appears substantially milder but is less rigorously characterized. CBD is a potent inhibitor of cytochrome P450 enzymes CYP3A4 and CYP2C19, creating clinically significant drug interactions: it can increase plasma levels of clobazam (and its active metabolite norclobazam), warfarin, certain antiepileptics, and other CYP3A4/2C19 substrates, necessitating therapeutic drug monitoring when co-administered. CBD is contraindicated or requires close medical supervision in individuals with hepatic impairment, those taking hepatotoxic medications, or those on narrow therapeutic index drugs metabolized by CYP3A4 or CYP2C19. Safety data in pregnancy and lactation are insufficient to establish a risk profile; given that cannabinoids cross the placental barrier and are detected in breast milk, use during pregnancy and breastfeeding is not recommended absent compelling medical indication.